Journals / Turkish Journal of Medical Sciences / 2020 / Cilt: 50 - Sayı: 5

Colchicine intolerance in FMF patients and primary obstacles for optimal dosing

Pages
1337–1343
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Suboptimal colchicine dosing is associated with complications.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: Colchicine is the mainstay of treatment in FMF.
📊
Key Findings & Data:Materials and methods: All patients were recruited from “FMF in Central Anatolia” (FiCA) cohort, 915 adults with a minimum followup time of 6 months during which they had obeyed all treatment instructions.
💡
Conclusion & Impact:Suboptimal colchicine dosing is associated with complications.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aim: Colchicine is the mainstay of treatment in FMF. However, in daily practice it is not easy to maintain effective colchicine doses in a substantial number of patients due to its side effects. In this study, we aimed to investigate prevalence and risk factors for colchicine side effects that limit optimal drug dosing and cause permanent discontinuation. Materials and methods: All patients were recruited from “FMF in Central Anatolia” (FiCA) cohort, 915 adults with a minimum followup time of 6 months during which they had obeyed all treatment instructions. Demographic and anthropometric data, FMF disease characteristics, disease severity, complications, and treatment features were recorded on a web-based registry. Prevalence of colchicine intolerance and characteristics of intolerant patients were analyzed. Results: Effective colchicine doses cannot be maintained in 172 (18.7%) subjects. Main side effects that limit optimal dosing were as follows: diarrhea in 99 (10.8%), elevation in transaminases in 54 (5.9%), leukopenia in 10 (%1.1), renal impairment in 14 (1.3%), myopathy in five (0.5%), and allergic skin reaction in two. Colchicine had to be permanently ceased in 18 (2%) patients because of serious toxicity. Male sex and obesity were found to be associated with liver toxicity, and having a normal body weight was associated with diarrhea. Chronic inflammation and proteinuria were more common in colchicine-intolerant patients, and they had reported more frequent attacks compared to those tolerating optimal doses. Conclusion: Colchicine intolerance is an important problem in daily clinical practice, mainly due to diarrhea and liver toxicity. Suboptimal colchicine dosing is associated with complications.

🔖

Cite This Article

BİLGE, N. Ş. Y., BODAKÇI, E., KAŞİFOĞLU, T., YAPAR, D., HAZNEDAROĞLU, Ş., YARDIMCI, G. K., ATAŞ, N., GÖKER, B., SALMAN, R. B., TUFAN, A., SATIŞ, H., BABAOĞLU, H., ARMAĞAN, B., KALYONCU, U., SARI, A., KILIÇ, L. (2022). Colchicine intolerance in FMF patients and primary obstacles for optimal dosing. Turkish Journal of Medical Sciences, Cilt: 50 - Sayı: 5, 1337–1343. https://ajindex.com/articles/609800

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Sönmez HE, Batu ED, Özen S. Familial Mediterranean fever: current perspectives. Journal of Inflammation Research 2016
  2. 20 doi: 10.2147/JIR.S91352 2. Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E et al. EULAR recommendations for the management of familial Mediterranean fever. Annals of the Rheumatic Diseases 2016
  3. 75 (4): 644-651. doi: 10.1136/annrheumdis-2015-208690 3. Tunca M, Akar S, Onen F, Ozdogan H, Kasapcopur O et al. Familial Mediterranean fever (FMF) in Turkey: Results of a nationwide multicenter study. Medicine 2005
  4. 84 (1): 1-11. doi: 10.1097/01.md0000152370.846280 4. Zemer D, Revach M, Pras M, Modan B, Schor S et al. A controlled trial of colchicine in preventing attacks of familial Mediterranean fever. New England Journal of Medicine 1974
  5. 291 (18): 932-934. doi: 10.1056/NEJM197410312911803 5. Dinarello CA,Wolfe S, Goldfinger SE, Dale DC, Alling DW, et al. Colchicine therapy for familial Mediterranean fever: a double-blind trial. New England Journal of Medicine 1974
  6. 291 (18): 934-937. doi: 10.1056/NEJM197410312911804 6. Zemer D, Pras M, Sohar E, Modan M, Cabili S et al. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. New England Journal of Medicine 1986
  7. 314 (16): 1001-1005. doi: 10.1056/NEJM/198604173141601 7. Kasifoglu T, Bilge SY, Sari İ, Solmaz D, Senel S et al. Amyloidosis and its related factors in Turkish patients with familial Mediterranean fever: A multicentre study. Rheumatology 2013
  8. 53(4):741-745. doi: 10.1093/rheumatology/ket400 8. Slobodnick A, Shah B, Pillinger M.H, Krasnokutsky S. Colchicine: old and new. The American Journal of Medicine 2015
  9. 128 (5): 461-470. doi: 10.1016/j.amjmed.2014.12.010 9. Kuncl RW, Duncan G. Chronic human colchicine myopathy and neuropathy. New England Journal of Medicine 1988
  10. 45 (3): 245-246.doi: 10.1056/NEJM198706183162502 10. Oh DH, Chan SQ, Wilson AM. Myopathy and possible intestinal dysfunction in a patient treated with colchicine and simvastatin. The Medical Journal of Australia 2012
  11. 197 (6): 332-333. doi: 10.5694/mja12.10333 11. Tufan A, Dede D, Cavus S, Altintas ND, Iskit AB et al. Rhabdomyolysis in a patient treated with colchicine and atorvastatin. Ann Pharmacotherapy 2006
  12. 40 (7-8): 1466-9.doi: 10.1345/aph.1H064 12. Livneh A, Langevitz P, Zemer D, Zaks N, Kees S et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheumatism 1997
  13. 40 (10): 1879-85.doi: 10.1002/ art.1780401023 13. Demirkaya E, Acikel C,